CNS Research, CNS Discovery, pRED, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland.
Psychopharmacology (Berl). 2012 Jul;222(2):203-14. doi: 10.1007/s00213-012-2636-x. Epub 2012 Jan 18.
Ro 64-6198, the prototypical non-peptide nociceptin/orphanin FQ peptide (NOP) receptor agonist, has potent anxiolytic-like effects in several preclinical models and species. However the effects of Ro 64-6198 on distinctive anxiety-provoking conditions related to unconditioned conflict behavior as well as its role in despair-like behavior remain to be addressed.
Here we examined the effects of Ro 64-6198 on unconditioned conflict anxiety using stimuli with different salience and on regulation of autonomic reactivity and compared these to the effects of benzodiazepine receptor agonists. We also addressed the potential effects of Ro 64-6198 on despair-like behavior.
Ro 64-6198 (0.1 to 10 mg/kg i.p.) and either diazepam or chlordiazepoxide were tested in the Vogel conflict punished drinking test (VCT) in Sprague Dawley rats, in the social approach-avoidance (SAA) test in Lewis rats, in the novelty-induced hypophagia (NIH) in C57BL/6J mice, and in stress-induced hyperthermia in NMRI mice, as well as in the forced swim test (FST) in Sprague Dawley rats and the tail suspension test (TST) in C57BL/6J mice.
Ro 64-6198 (0.3 to 3 mg/kg) dose-dependently produced anxiolytic-like effects in the VCT, SAA, NIH, and SIH, similar to benzodiazepine receptor agonists. Ro 64-6198 did not alter immobility time in the FST and TST.
Ro 64-6198 produced marked anxiolytic-like effects in response to a variety of mild to strong anxiogenic stimuli, whereas it did not facilitate depression-related behaviors. This data extend previous literature suggesting that NOP receptors are a viable target for the treatment of anxiety disorders.
Ro 64-6198 是一种典型的非肽类孤啡肽/孤儿受体激动剂,在几种临床前模型和物种中具有很强的抗焦虑样作用。然而,Ro 64-6198 对与非条件冲突行为相关的独特的诱发焦虑的条件以及它在绝望样行为中的作用仍有待解决。
本文研究了 Ro 64-6198 对使用不同显著性刺激的非条件冲突焦虑的影响,并对其与苯二氮䓬受体激动剂的作用进行了比较。我们还探讨了 Ro 64-6198 对绝望样行为的潜在影响。
在 Sprague Dawley 大鼠的 Vogel 冲突惩罚性饮水试验(VCT)、Lewis 大鼠的社交接近-回避试验(SAA)、C57BL/6J 小鼠的新奇性诱导摄食减少试验(NIH)和 NMRI 小鼠的应激诱导性体温升高试验中,以及在 Sprague Dawley 大鼠的强迫游泳试验(FST)和 C57BL/6J 小鼠的悬尾试验(TST)中,测试了 Ro 64-6198(0.1 至 10 mg/kg,腹腔注射)和地西泮或氯氮䓬。
Ro 64-6198(0.3 至 3 mg/kg)剂量依赖性地产生了 VCT、SAA、NIH 和 SIH 的抗焦虑样作用,类似于苯二氮䓬受体激动剂。Ro 64-6198 并未改变 FST 和 TST 中的不动时间。
Ro 64-6198 对各种轻度至强烈的致焦虑刺激产生了明显的抗焦虑样作用,而对与抑郁相关的行为没有促进作用。这一数据扩展了先前的文献,表明孤啡肽受体是治疗焦虑障碍的一个可行靶点。